Product/Composition:- | Dolutegravir + Rilpivirine |
---|---|
Strength:- | 50 mg / 25 mg |
Form:- | Tablet |
Reference Brands:- | Juluca(EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Dolutegravir + Rilpivirine, sold as Juluca, is a once-daily, two-drug HIV-1 maintenance therapy for virologically suppressed adults. It offers effective viral suppression with fewer side effects and is approved by the FDA and EMA.
Dolutegravir + Rilpivirine, marketed as Juluca, is a once-daily, two-drug regimen for the maintenance treatment of HIV-1 infection. It combines Dolutegravir, an integrase strand transfer inhibitor (INSTI), and Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), to effectively suppress HIV replication. Approved by the US FDA and EMA, Juluca is intended for adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure. Juluca offers a simplified treatment option with fewer drugs, reduced side effects, and excellent tolerability, making it ideal for long-term HIV management.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications